MEPSGEN plans to IPO in 2025
2023-09-27
MEPS-AMS is the answer to the rapid advancement of MPS
2023-09-26
MEPSGEN's expertise in both MPS and nanoparticle technologies
2023-09-25
Korea should kick off national-level project to end animal-testing
2023-09-19
South Korea's national assembly must pass the VAAM act to become a first mover
2023-09-18
MEPSGEN's MPS chip will lead the global drug evaluation platform market
2023-09-08
To network with amazing people at KAATC
2023-09-07
Which non-clinical platform will fill the gap?
2023-08-09
CEO YongTae Kim shares his thoughts on how blood-brain-barrier-on-a-chip could improve the drug development process
2023-08-02
Mepsgen targets CRO business with its scalable microphysiological system solution
2023-07-18
[BIOPLUS-INTERPHEX (BIX) KOREA 2023] Mepsgen attends BIX
2023-07-11
New Research Paper titled "Manufactured Tissue-to-Tissue Barrier Chip for Modeling the Human Blood-Brain Barrier and Regulation of Cellular Trafficking."
2023-06-30
[Bio TV] Get an inside look at the mind of CEO YongTae Kim!
2023-06-27
[2023 MPS World Summit] MEPSGEN's participation in 2023 MPS World Summit
2023-06-23
[CVB 2023] MEPSGEN's participation in CVB2023
2023-06-16
Exclusive interview with Dr. Robert Langer, founder of Moderna, and YongTae Kim, CEO of Mepsgen, leading domestic MPS (microphysiological systems) Innovator.
2023-06-09
Dr. Robert Langer Engages in Discussion with MEPSGEN CEO YongTae Kim on the "Strength and Potential of K-Biotech" at Bio USA 2023 Satellite Event KBTP 2023
2023-06-08
Company Presentation at Bio International Convention 2023_MEPSGEN
2023-06-07
K-Bio 544 Companies Converge in Boston, USA... Accelerating Global Expansion.
[BIO International Convention 2023] Come visit us at Booth #2464 (The Korea Pavilion)
2023-06-05
